4DMT Reports Strong 2025 Results, Major Otsuka Partnership, Extended Cash Runway, and Clinical Progress

summarizeSummary

4D Molecular Therapeutics reported strong full-year 2025 financial results, highlighted by a major strategic partnership with Otsuka Pharmaceutical, successful financing, and significant clinical trial advancements, extending its cash runway into H2 2028.

check_boxKey Events

• Strategic Partnership with Otsuka Pharmaceutical

  Entered a strategic partnership for 4D-150 in the Asia-Pacific region, receiving an $85 million upfront cash payment in Q4 2025, with an expectation of at least $50 million in cost sharing over the next three years and eligibility for up to $336 million in potential regulatory and commercial milestones plus tiered double-digit royalties.

• Extended Cash Runway into H2 2028

  Reported $514 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which, combined with expected payments from the Otsuka collaboration, is projected to fund operations into the second half of 2028.

• Significant Clinical Progress for Lead Programs

  Completed enrollment in the 4D-150 4FRONT-1 wet AMD Phase 3 trial ahead of projections, with topline data expected in H1 2027. Also announced positive long-term interim results for 4D-150 (wet AMD) and 4D-710 (CF lung disease) Phase 1/2 clinical trials.

• Strengthened Balance Sheet with $118M Financing

  Secured an equity investment of up to $11 million from the Cystic Fibrosis Foundation and raised gross proceeds of $10 million through an at-the-market offering and $100 million from an equity offering in Q4 2025.

auto_awesomeAnalysis

This 8-K filing details a highly positive year for 4D Molecular Therapeutics, marked by a significant strategic partnership with Otsuka Pharmaceutical, which provided an $85 million upfront payment and substantial future cost sharing and milestones. This, combined with other financing activities, has extended the company's cash runway into the second half of 2028, significantly de-risking its operations. Furthermore, the company reported strong clinical progress, including the completion of enrollment for its lead 4D-150 wet AMD Phase 3 trial ahead of schedule and positive long-term data for both 4D-150 and 4D-710 programs. These developments collectively provide a strong foundation for future growth and clinical execution, bolstering investor confidence.